Does postoperative polymyxin B hemoperfusion improve survival in patients with abdominal septic shock?
Postoperative polymyxin B hemoperfusion does not appear to provide a survival benefit in patients with abdominal septic shock, highlighting the need for prospective randomized trials.
In this retrospective study, postoperative polymyxin B hemoperfusion did not show any survival benefit for the overall study population or any of the studied subgroups of patients with abdominal septic shock. A large multicentered prospective randomized trial is warranted to identify the true role of polymyxin B hemoperfusion in sepsis caused by Gram-negative bacteria.
Iwagami et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: